The FDA says the nationwide shortage for Ozempic and Wegovy is over, but as CBS News New York's Ali Bauman explains, that supply change could lead to consumers paying more.

The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

Feb. 21, the Food and Drug Administration said there is no longer a short supply of the weight loss and diabetes drugs Wegovy ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Drugs like Ozempic, Wegovy, and Mounjaro have demonstrated remarkable ... offers a direct payment program that allows some patients to purchase the drug for $399 per month. While these discounts ...

Semaglutide has been on the market for 20 years, but it was approved by the FDA in 2021 for chronic weight management. Since then, Novo Nordisk (Wegovy and Ozempic) and Eli Lilly (Mounjaro and ...